Giuseppe Nasso, Claudio Larosa, Francesco Bartolomucci, Mario Siro Brigiani, Gaetano Contegiacomo, Maria Antonietta Demola, Walter Vignaroli, Alessandra Tripoli, Cataldo Girasoli, Rosanna Lisco, Marialisa Trivigno, Roberto Michele Tunzi, Tommaso Loizzo, Dritan Hila, Rosalba Franchino, Vincenzo Amodeo, Simone Ventra, Giuseppe Diaferia, Giacomo Schinco, Felice Eugenio Agrò, Maddalena Zingaro, Isabella Rosa, Roberto Lorusso, Armando Del Prete, Giuseppe Santarpino, Giuseppe Speziale
Background . The in-hospital reduction in low-density lipoprotein cholesterol (LDL-C) levels following acute coronary syndrome (ACS) is recommended in the current clinical guidelines. However, the efficacy of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors in those patients undergoing coronary artery bypass graft (CABG) has never been demonstrated. Methods . From January 2022 to July 2023, we retrospectively analyzed 74 ACS patients characterized by higher LDL-C levels than guideline targets and who underwent coronary bypass surgery...
February 4, 2024: Journal of Clinical Medicine